AMAP-102

AMAP-102 is a serotonin 5-HT_2B and 5-HT_2C receptor antagonist which is or was under development for the treatment of musculoskeletal pain and rheumatoid arthritis.^[1][2][3] It is taken by mouth.^[1]

AMAP-102

Clinical data
Other names	AMAP102
Routes of administration	Oral[1]
Drug class	Serotonin 5-HT2B receptor antagonist; Serotonin 5-HT2C receptor antagonist

The drug is or was under development by AnaMar AB.^[1][2][3] A phase 1 clinical trial was completed in 2009 and the results of a phase 2 trial were reported in 2014.^[1] It failed to reduce inflammatory pain in people with osteoarthritis in this trial and its development was said to have been discontinued.^[1] However, the drug is still listed as being in active development as of January 2025.^[2][3] The chemical structure of AMAP-102 does not appear to have been disclosed.^[1][2][3]